As many of you may know, this week saw Clinuvel hold its Annual General Meeting in the Melbourne Town Hall. As managing director I welcome these opportunities where I am able to meet and talk to the people whom Clinuvel considers integral to the company and its existence; the Board of Directors sees Clinuvel’s investors as unique. In Clinuvel, an investor has to fundamentally believe in the premise of offering pharmaceutical photoprotection, a novel option, an innovative approach to skin disorders.
In a meeting that would be considered short by international standards I was both excited and proud to present some of the achievements and milestones our team has reached this year, and lay out our plans for the next 12 months.
A new initiative has just launched in the UK with the goal of increasing awareness and support for the more widespread use of 
During more than a decade of clinical research on Clinuvel’s proprietary drug 
EPP is a rare condition, and the most acute indication for which we are exploring a clinical treatment with afamelanotide. Simply put, EPP is an absolute light intolerance brought about by a build up of photosensitive compounds in the skin of the sufferer.
In Clinuvel’s search to demonstrate the effect of its drug to reduce symptoms caused by light in the visible and invisible spectrum, the team has started to carry out human trials in Photodynamic Therapy (PDT). This indication stands out among Clinuvel’s current series of clinical trials as it is aimed at reducing symptoms caused by another cancer treatment (adjunct treatment details can be found 
